and female [50,000/mm:<150,000/mm 3 , resume with the daily dose reduced by 25 mg (if taking 25 mg once daily, resume with 12.5 mg once daily) Platelet count >400,000/mm 3 after 2 weeks at the lowest dose: Discontinue treatment Chronic hepatitis C-associated thrombocytopenia: Oral: Note: Use the lowest dose to achieve the target platelet count necessary to initiate antiviral therapy (peginterferon and ribavirin) or to avoid dose reductions of peginterferon during antiviral therapy. Discontinue when antiviral therapy is stopped. Initial: 25 mg once daily; dose should be titrated based on platelet response. Maximum dose: 100 mg/day Dosage adjustment based on platelet response: Platelet count> <50,000/mm 3 (after at least 2 weeks): Increase daily dose by 25 mg every 2 weeks; maximum dose: 100 mg/day Platelet count 200,000/mm 3 and 400,000/mm 3 (at any time): Reduce daily dose by 25 mg; reassess in 2 weeks Platelet count >400,000/mm 3 : Withhold dose; assess platelet count twice weekly; when platelet count> <150,000/mm 3 , resume with the daily dose reduced by 25 mg (if taking 25 mg once daily, resume with 12.5 mg once daily) Platelet count >400,000/mm 3 after 2 weeks at the lowest dose: Discontinue treatment Severe aplastic anemia: Oral: Note: Use the lowest dose to achieve and maintain hematologic response. Hematologic response may take up to 16 weeks and requires dose titration. Discontinue therapy if hematologic response is not achieved after 16 weeks of treatment, for excessive platelet responses or for liver function abnormalities. Consider discontinuing if new cytogenetic abnormalities are observed. Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity); dose should be titrated based on platelet response. Maximum dose: 150 mg/day. Dosage adjustment based on platelet response: Platelet count> <50,000/mm 3 ( 2 weeks after treatment initiation or a dose increase): Increase daily dose by 50 mg (if taking 25 mg once daily, increase dose to 50 mg once daily prior to increasing the dose amount by 50 mg daily); maximum: 150 mg/day Platelet count 200,000/mm 3 and 400,000/mm 3 (at any time): Reduce daily dose by 50 mg; reassess in 2 weeks Platelet count >400,000/mm 3 : Withhold dose for 1 week; when platelet count> <150,000/mm 3 , resume with the daily dose reduced by 50 mg Platelet count >400,000/mm 3 after 2 weeks at the lowest dose: Discontinue treatment For patients who achieve tri-lineage response, including transfusion independence, lasting at least 8 weeks, may reduce the dose by 50%. If counts remain stable after 8 weeks at the reduced dose, discontinue and monitor blood counts. If platelets counts drop to> <30,000/mm 3 , hemoglobin to> <9 g/dL, or ANC to> <500/mm 3 , may reinitiate at the prior effective dose. Dosing: Geriatric Refer to adult dosing. Dosing: Pediatric Note: Do not use eltrombopag to normalize platelet counts. Chronic immune (idiopathic) thrombocytopenia (ITP): Note: Use the lowest dose to achieve and maintain platelet count 50,000/mm 3 as needed to reduce the risk of bleeding. Discontinue if platelet count does not respond to a level that avoids clinically important bleeding after 4 weeks at the maximum of 75 mg/day. Children 1 to 5 years: Oral: Initial: 25 mg once daily; dose should be titrated based on platelet response (no dosage adjustment required for patients of East Asian ancestry). Maximum dose: 75 mg/day. Children 6 years and Adolescents: Oral: Refer to adult dosing Dosing: Renal Impairment No dosage adjustment is necessary. Dosing: Hepatic Impairment Adjustment for hepatic impairment prior to initiating treatment: Chronic ITP: Note: In patients with ITP and hepatic impairment, wait 3 weeks (instead of 2 weeks) after therapy initiation or subsequent dosage changes prior to increasing dose. Mild, moderate, or severe impairment (Child-Pugh classes A, B, or C): Initial: 25 mg once daily Patients of East-Asian ethnicity with hepatic impairment (Child-Pugh classes A, B, or C): Initial: Consider 12.5 mg once daily Chronic hepatitis C-associated thrombocytopenia: Initial: No dosage adjustment is necessary Severe aplastic anemia: Mild, moderate, or severe impairment (Child-Pugh classes A, B, or C): Initial: 25 mg once daily Adjustment for hepatic impairment during treatment: ALT levels 3 times the upper limit of normal (ULN) in patients with normal hepatic function or 3 times baseline in those with preexisting transaminase elevations and which are progressive, persistent ( 4 weeks), accompanied by increased direct bilirubin, or accompanied by clinical signs of liver injury or evidence of hepatic decompensation: Discontinue treatment. Hepatotoxicity may recur with re-treatment after therapy interruption, but if determined to be clinically beneficial, may cautiously resume treatment; monitor ALT weekly during dosage titration; permanently discontinue if liver function test elevations persist, worsen, or recur. Reconstitution The oral suspension must be reconstituted with cool or cold water only (do not use hot water). Fill the provided oral syringe with 20 mL of drinking water and empty into the mixing bottle. Add the appropriate eltrombopag dose to the mixing bottle; gently and slowly shake the bottle for at least 20 seconds to mix. If not used immediately, suspension may be stored for up to 30 minutes at room temperature; discard any solution if not used within 30 minutes. Following administration, discard suspension remaining in bottle in trash (do not dispose of in drain); clean supplies by removing plunger from oral syringe, rinse bottle, lid, syringe, and plunger under running water and air-dry (bottle may stain, this is normal); wash hands with soap and water. If powder or suspension spills during preparation or administration, consider wearing disposable gloves during spill clean-up to avoid staining skin. Administration Administer on an empty stomach, 1 hour before or 2 hours after a meal. Swallow tablets whole; do not crush and mix with food or liquids. Prepare the suspension with cool or cold water only (do not use hot water); discard any suspension not administered within 30 minutes after reconstitution. If powder or suspension spills during preparation or administration, consider wearing disposable gloves during spill clean-up to avoid staining skin. Do not administer concurrently with antacids, foods high in calcium, or minerals (eg, iron, calcium, aluminum, magnesium, selenium, zinc); administer eltrombopag at least 2 hours before and 4 hours after. Do not administer more than one dose within 24 hours. Dietary Considerations Food, especially dairy products, may decrease the absorption of eltrombopag. Storage Oral suspension: Store at 20 C to 25 C (68 F to 77 F); excursions permitted to 15 C to 30 C (59 F to 86 F). Once reconstituted (if not used immediately), the suspension may be stored for a maximum of 30 minutes between 20 C and 25 C (68 F to 77 F); excursions permitted to 15 C to 30 C (59 F to 86 F). Discard the mixture if not used within 30 minutes. Tablets: Store at 20 C to 25 C (68 F to 77 F); excursions are permitted between 15 C and 30 C (59 F and 86 F). If present, do not remove desiccant. Dispense in original bottle. Drug Interactions Aluminum Hydroxide: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any aluminum-containing product. Consider therapy modification Asunaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Asunaprevir. Avoid combination BCRP/ABCG2 Substrates: Eltrombopag may increase the serum concentration of BCRP/ABCG2 Substrates. Monitor therapy Calcium Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any calcium-containing product. Consider therapy modification CycloSPORINE (Systemic): May decrease the serum concentration of Eltrombopag. Monitor therapy Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone. Monitor therapy Eluxadoline: Eltrombopag may increase the serum concentration of Eluxadoline. Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with eltrombopag and monitor patients for increased eluxadoline effects/toxicities. Consider therapy modification Grazoprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Grazoprevir. Avoid combination Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. Avoid combination Iron Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product. Exceptions: Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose. Consider therapy modification Magnesium Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product. Consider therapy modification Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any multivitamin containing polyvalent cations. Consider therapy modification Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any multivitamin containing polyvalent cations. Consider therapy modification OATP1B1/SLCO1B1 Substrates: Eltrombopag may increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Monitor therapy PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. Avoid combination Rosuvastatin: Eltrombopag may increase the serum concentration of Rosuvastatin. Management: Consideration a preventive 50% reduction in rosuvastatin adult dose when starting this combination; Canadian labeling recommends limiting rosuvastatin to a maximum of 20 mg/day. Consider therapy modification Selenium: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any selenium-containing product. Consider therapy modification Sucralfate: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of sucralfate. Consider therapy modification Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. Consider therapy modification Voxilaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Voxilaprevir. Avoid combination Zinc Salts: May decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any zinc-containing product. Consider therapy modification Adverse Reactions Adverse reactions and incidences reported are associated with adults unless otherwise indicated. >10%: Central nervous system: Fatigue (ITP: 5%; chronic hepatitis C: 28%; aplastic anemia: 28%), headache (ITP: 10%; chronic hepatitis C: 21%; aplastic anemia 21%), insomnia (chronic hepatitis C: 16%), chills (chronic hepatitis C: 14%), dizziness (aplastic anemia: 14%) Dermatologic: Pruritus (chronic hepatitis C: 15%), ecchymosis (aplastic anemia: 12%) Gastrointestinal: Nausea (ITP: 4% to 9%; chronic hepatitis C: 19%; aplastic anemia 33%), diarrhea (aplastic anemia: 21%; chronic hepatitis C: 19%; ITP: 3% to 9%; children and adolescents: 9%), appetite decreased (chronic hepatitis C: 18%), abdominal pain (aplastic anemia 12%; children and adolescents: 8%) Hematologic & oncologic: Anemia (chronic hepatitis C: 40%), febrile neutropenia (aplastic anemia: 14%) Hepatic: Hyperbilirubinemia (total bilirubin 1.5 x ULN: 76%; ITP and chronic hepatitis C: 3% to 8%), increased serum transaminases (aplastic anemia: 12%), abnormal hepatic function (ITP: 11%), increased serum ALT (children and adolescents: 6%; ITP: 6%), increased serum AST (ITP: 5%; children and adolescents: 4%) Neuromuscular & skeletal: Limb pain (aplastic anemia: 19%), weakness (chronic hepatitis C: 16%), arthralgia (aplastic anemia: 12%), muscle spasm (aplastic anemia: 12%), myalgia (ITP and chronic hepatitis C: 5% to 12%) Respiratory: Cough (aplastic anemia: 23%; chronic hepatitis C: 15%; children and adolescents: 9%), flu-like syndrome (chronic hepatitis C: 18%), upper respiratory infection (children and adolescents: 17%; ITP: 7%), dyspnea (aplastic anemia: 14%), oropharyngeal pain (aplastic anemia: 14%; children and adolescents: 8%; ITP: 4%), nasopharyngitis (children and adolescents: 12%), rhinorrhea (aplastic anemia: 12%, children and adolescents: 4%) Miscellaneous: Fever (chronic hepatitis C: 30%; aplastic anemia: 14%; children and adolescents: 9%) 1% to 10%: Cardiovascular: Peripheral edema (chronic hepatitis C: 10%), thrombosis (chronic hepatitis C: 3%) Dermatologic: Alopecia (ITP: 2%; chronic hepatitis C: 10%), skin rash (chronic hepatitis C: 9%; aplastic anemia: 7%; children and adolescents: 5%; ITP: 3%) Gastrointestinal: Toothache (children and adolescents: 6%), vomiting (ITP: 6%), xerostomia (ITP: 2%) Genitourinary: Urinary tract infection (ITP: 5%) Hematologic & oncologic: Thrombocytopenia (chronic hepatitis C: 3%) Hepatic: Alkaline phosphatase increased (ITP: 2%) Infection: Influenza (ITP: 3%) Neuromuscular & skeletal: Back pain (ITP: 3%), paresthesia (ITP: 3%), musculoskeletal pain (ITP: 2%) Ophthalmic: Cataract (ITP and chronic hepatitis C: 4% to 8%) Respiratory: Rhinitis (children and adolescents: 9%), pharyngitis (ITP: 4%)> <1%, postmarketing, and/or case reports: Abdominal distension, constipation, decreased visual acuity, deep vein thrombosis, desquamation, drowsiness, dry eye syndrome, dysesthesia, dysgeusia, dyspepsia, eye pain, facial swelling, fecal discoloration, foreign body sensation, glossalgia, hemorrhage, hemorrhoids, hot flash, hyperhidrosis, hypoesthesia, hypokalemia, increased hemoglobin, increased lacrimation, increased serum albumin, increased serum creatinine, increased serum total protein, lesion (hepatic), local inflammation (wound), malaise, malignant neoplasm (rectosigmoid), night sweats, oral herpes, oropharyngeal blistering, ostealgia, portal vein thrombosis, pulmonary embolism, pulmonary infarct, retinal hemorrhage, retinal pigment changes, sinus tachycardia, skin discoloration (including hyperpigmentation and skin yellowing), sleep disorder, superficial thrombophlebitis, tachycardia, thromboembolic complications, thrombotic microangiopathy (with acute renal failure), upper abdominal pain, urticaria, vertigo ALERT: U.S. Boxed Warning Hepatotoxicity In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended. Warnings/Precautions Concerns related to adverse effects: Cataract formation: Cataract formation or worsening was observed in clinical trials. Monitor regularly for signs and symptoms of cataracts; obtain ophthalmic exam at baseline and during therapy. Use with caution in patients at risk for cataracts (eg, advanced age, long-term glucocorticoid use). Hepatotoxicity: [US Boxed Warning]: Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended. Liver enzyme elevations may occur; obtain ALT, AST, and bilirubin prior to treatment initiation, every 2 weeks during adjustment phase, then monthly (after stable dose established). Eltrombopag inhibits UGT1A1 and OATP1B1, which may lead to indirect hyperbilirubinemia; obtain fractionation for elevated bilirubin levels. Repeat abnormal liver function tests within 3 to 5 days; if confirmed abnormal, monitor weekly until resolves, stabilizes, or returns to baseline. Discontinue treatment for ALT levels 3 times the upper limit of normal (ULN) in patients with normal hepatic function, or 3 times baseline (or >5 times ULN; whichever is lower) in those with preexisting transaminase elevations and which are progressively increasing, or persistent ( 4 weeks), or accompanied by increased direct bilirubin, or accompanied by clinical signs of liver injury or evidence of hepatic decompensation. Hepatotoxicity may recur with re-treatment after therapy interruption; however, if the benefit of treatment outweighs the hepatotoxicity risk, initiate carefully, and monitor liver function tests weekly during the dose adjustment phase. Permanently discontinue if liver test abnormalities persist, worsen, or recur with rechallenge. In clinical trials, isolated cases of severe liver injury occurred, liver function test abnormalities usually occurred ~3 months after initiation of eltrombopag and resolved with discontinuation. Thromboembolism: Thromboembolism (venous or arterial) may occur with excessive increases in platelet levels. Use with caution in patients with known risk factors for thromboembolism (eg, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). Thrombotic events, primarily involving the portal venous system, were more commonly seen in eltrombopag-treated chronic hepatitis C patients with thrombocytopenia (when compared to placebo). Thrombotic events (including portal venous thrombosis) were also reported in a study of non-ITP thrombocytopenic patients with chronic liver disease undergoing elective invasive procedures receiving eltrombopag 75 mg once daily. Symptoms of portal vein thrombosis include abdominal pain, nausea, vomiting, and diarrhea. The risk for portal venous thrombosis is increased in thrombocytopenic patients with chronic liver disease receiving 75 mg once daily for 2 weeks as preparation for invasive procedures. Disease-related concerns: Chronic hepatitis C infection: [US Boxed Warning]: May increase risk of hepatic decompensation when used in combination with interferon and ribavirin in patients with chronic hepatitis C. In clinical trials, patients with low albumin (> <3.5 g/dL) or a Model for End-Stage Liver Disease (MELD) score 10 at baseline had an increased risk of hepatic decompensation; closely monitor these patients during therapy. If antiviral therapy is discontinued for hepatic decompensation according to interferon/ribavirin recommendations, eltrombopag should also be discontinued. Indirect hyperbilirubinemia is commonly observed with eltrombopag when used in combination with peginterferon and ribavirin. In addition, ascites, encephalopathy, and thrombotic events were reported more frequently than placebo in chronic hepatitis C trials. Hepatic impairment: Clearance may be reduced in patients with hepatic impairment; use with caution; reduced starting doses are recommended in patients with ITP (except children 1 to 5 years) and severe aplastic anemia who have hepatic impairment (no initial dose reductions are necessary in patients with chronic hepatitis C-related thrombocytopenia). Myelodysplastic syndromes: Eltrombopag is not indicated for the treatment of myelodysplastic syndromes (MDS). A clinical trial comparing the combination of azacitidine plus eltrombopag to azacitidine alone in patients with intermediate-1, intermediate-2, or high-risk MDS was terminated due to lack of efficacy and safety concerns (including increased progression to AML). Increased relative risks of death and progression to AML in the eltrombopag arm compared to placebo were observed in the study. Renal impairment: Use with caution with renal impairment (any degree) and monitor closely; initial dosage adjustment is not necessary. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations: East-Asian ethnicity (eg, Chinese, Japanese, Korean, Taiwanese): May have greater drug exposure (compared to non-East Asians); therapy should be initiated with lower starting doses in ITP and severe aplastic anemia patients. Other warnings/precautions: Appropriate use: Do not use to normalize platelet counts. ITP: Indicated only when the degree of thrombocytopenia and clinical conditions increase the risk for bleeding in patients with chronic immune ITP; use the lowest dose necessary to achieve and maintain platelet count 50,000/mm 3 . Discontinue if platelet count does not respond to a level to avoid clinically important bleeding after 4 weeks at the maximum recommended dose. Chronic hepatitis C-associated thrombocytopenia: Use only when thrombocytopenia prevents the initiation and maintenance of interferon-based therapy; discontinue if antiviral therapy is discontinued. Safety and efficacy have not been established when combined with direct acting antiviral medications approved for chronic hepatitis C genotype 1 infection therapy. Severe aplastic anemia: Use the lowest dose to achieve and maintain hematologic response. Discontinue if no hematologic response has occurred after 16 weeks of therapy, excessive platelet count responses or important liver test abnormalities. Consider discontinuation if new cytogenetic abnormalities are observed. Monitoring Parameters Monitor liver function tests, including ALT, AST, and bilirubin (baseline, every 2 weeks during dosage titration, then monthly after a stable dose is achieved; evaluate abnormal liver function tests within 3 to 5 days; monitor weekly until abnormalities resolve, stabilize, or return to baseline or if re-treating [not recommended] after therapy interruption for hepatotoxicity); bilirubin fractionation (for elevated bilirubin); ophthalmic exam (baseline and during treatment). Thrombocytopenia due to CHC and chronic ITP: CBC with differential and platelet count (weekly at initiation and during dosage titration, then monthly when stable; after cessation, monitor weekly for 4 weeks; when switching between the oral suspension and tablet, monitor platelet counts weekly for 2 weeks, then monthly when stable). Severe aplastic anemia: CBC with differential and platelets (regularly throughout therapy) Monitor adherence. Pregnancy Risk Factor C Pregnancy Considerations Adverse effects were observed in animal reproduction studies. A Promacta pregnancy registry has been established to monitor outcomes of women exposed to eltrombopag during pregnancy (1-888-825-5249). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience headache, insomnia, itching, lack of appetite, flu-like symptoms, cough, muscle pain, joint pain, rhinorrhea, rhinitis, sneezing, back pain, dizziness, pharyngitis, tooth pain, muscle spasms, or hair loss. Have patient report immediately to prescriber signs of a urinary tract infection (hematuria, burning or painful urination, polyuria, fever, lower abdominal pain, or pelvic pain), signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), signs of blood clots (numbness or weakness on one side of the body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; angina; shortness of breath; tachycardia; or coughing up blood), severe loss of strength and energy, severe abdominal vision changes, eye pain, severe eye irritation, burning or numbness feeling, severe nausea, vomiting, severe diarrhea, bruising, bleeding, mouth sores, mouth irritation, confusion, swelling of arms or legs, chills, or abdominal edema (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about eltrombopag Side Effects During Pregnancy Dosage Information Drug Interactions Support Group En Español 5 Reviews Add your own review/rating Drug class: platelet-stimulating agents Consumer resources Eltrombopag Eltrombopag Tablets Eltrombopag (Advanced Reading) Professional resources Eltrombopag (AHFS Monograph) Other brands: Promacta Related treatment guides Idiopathic Thrombocytopenic Purpura Aplastic Anemia Thrombocytopenia Thrombocytopenia Idiopathic> ]} Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Eltrombopag Rating 5 User Reviews 8.0 /10 5 User Reviews 8.0 Rate it! Drug Class Platelet-stimulating agents Related Drugs platelet-stimulating agents Promacta , Nplate , romiplostim , oprelvekin , Neumega Idiopathic Thrombocytopenic Purpura prednisone , triamcinolone , dexamethasone , Decadron , Deltasone , cortisone , More... Aplastic Anemia Promacta , Leukine , Atgam , sargramostim , lymphocyte immune globulin, anti-thy (equine) , More... Thrombocytopenia Idiopathic triamcinolone , Promacta , Kenalog-40 , More... 1 more conditions...} } keep at bay
to confess Eltrombopag in the present day
EmoticonEmoticon